565 related articles for article (PubMed ID: 19487300)
1. Adaptive therapy.
Gatenby RA; Silva AS; Gillies RJ; Frieden BR
Cancer Res; 2009 Jun; 69(11):4894-903. PubMed ID: 19487300
[TBL] [Abstract][Full Text] [Related]
2. Erratum: High-Throughput Identification of Resistance to Pseudomonas syringae pv. Tomato in Tomato using Seedling Flood Assay.
J Vis Exp; 2023 Oct; (200):. PubMed ID: 37851522
[TBL] [Abstract][Full Text] [Related]
3. Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
Ibrahim-Hashim A; Robertson-Tessi M; Enriquez-Navas PM; Damaghi M; Balagurunathan Y; Wojtkowiak JW; Russell S; Yoonseok K; Lloyd MC; Bui MM; Brown JS; Anderson ARA; Gillies RJ; Gatenby RA
Cancer Res; 2017 May; 77(9):2242-2254. PubMed ID: 28249898
[TBL] [Abstract][Full Text] [Related]
4. A theoretical quantitative model for evolution of cancer chemotherapy resistance.
Silva AS; Gatenby RA
Biol Direct; 2010 Apr; 5():25. PubMed ID: 20406443
[TBL] [Abstract][Full Text] [Related]
5. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
[TBL] [Abstract][Full Text] [Related]
6. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.
Hamis S; Nithiarasu P; Powathil GG
J Theor Biol; 2018 Oct; 454():253-267. PubMed ID: 29909142
[TBL] [Abstract][Full Text] [Related]
7. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
[TBL] [Abstract][Full Text] [Related]
8. Dosage strategies for delaying resistance emergence in heterogeneous tumors.
Vakil V; Trappe W
FEBS Open Bio; 2021 May; 11(5):1322-1331. PubMed ID: 33638275
[TBL] [Abstract][Full Text] [Related]
9. Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?
Ledzewicz U; Schättler H
Cancer Lett; 2017 Aug; 401():74-80. PubMed ID: 28323033
[TBL] [Abstract][Full Text] [Related]
10. Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
Cho H; Levy D
J Theor Biol; 2018 Jan; 436():120-134. PubMed ID: 29030212
[TBL] [Abstract][Full Text] [Related]
11. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
13. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Evolutionary analysis of replicator dynamics about anti-cancer combination therapy.
Zhao R; Lai X
Math Biosci Eng; 2023 Jan; 20(1):656-682. PubMed ID: 36650783
[TBL] [Abstract][Full Text] [Related]
16. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
17. Towards Multidrug Adaptive Therapy.
West J; You L; Zhang J; Gatenby RA; Brown JS; Newton PK; Anderson ARA
Cancer Res; 2020 Apr; 80(7):1578-1589. PubMed ID: 31948939
[TBL] [Abstract][Full Text] [Related]
18. Evolutionary approaches to prolong progression-free survival in breast cancer.
Silva AS; Kam Y; Khin ZP; Minton SE; Gillies RJ; Gatenby RA
Cancer Res; 2012 Dec; 72(24):6362-70. PubMed ID: 23066036
[TBL] [Abstract][Full Text] [Related]
19. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
[TBL] [Abstract][Full Text] [Related]
20. Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer.
Brown JS; Cunningham JJ; Gatenby RA
IEEE Trans Biomed Eng; 2017 Mar; 64(3):512-518. PubMed ID: 28113286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
